RT Journal Article SR Electronic T1 Doxofylline: Efficacy and safety in complex treatment of COPD JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP p864 VO 38 IS Suppl 55 A1 Tetyana Pertseva A1 Kateryna Gashynova A1 Natalia Klimenko YR 2011 UL http://erj.ersjournals.com/content/38/Suppl_55/p864.abstract AB Aim of study: To evaluate efficacy and safety of Aerofylline, ABC Farmaceutici (doxofylline) in patients with stable COPD.Study population and methods: 30 out-patients (pts) with stable COPD, stage II were divided on two groups: 15 pts (11 men, mean age 47.5±8.6 yrs) treated with inhaled bronchodilators and doxofylline 400 mg bid (Group 1) and 15 pts (12 men, mean age 50.3±9.0 yrs), treated with inhaled bronchodilators only (Group 2).Pulmonary function tests, respiratory muscles fatigue (by MasterLab, Jager), Holter ECG and dyspnoea (by MRC score) were evaluated in all pts before and 30 days after start of treatment.Results: Both groups were similar regarding to age, sex, duration of disease, FEV1, PImax, and dyspnoea level at the beginning of treatment.30 days after start of treatment the results were following: FEV1 did not change statistically significant in both groups. At the same time, dyspnoea score decrease significantly in Groupe 1 but not in Group II (down to 0.7±0.4 scores and 1.9±0.5 scores respectively). PImax in Groupe 1 increase on 21.3%, in Group 2 – on 11.9% only.We did not find any difference in tachycardia and premature beat rate between the groups.Conclusions: Doxofilline did not improve pulmonary function, but significantly decrease respiratory muscles fatigue and dyspnoea in patients with COPD, stage II.Doxifilline did not influence significantly on a heart rhythm.